We are pleased to announce that on Tuesday 6th April 2021, REPROCELL launched a new testing service for the identification for Covid-19 variants using the Allplex SARS-CoV-2 Variants I Assay (referred to below as Allplex) manufactured by Seegene Inc. (South Korea). This will be offered in addition to full screening test for Covid-19 using cutting-edge SmartAmp technology that REPROCELL launched on March 1st 2021.
22 March 2021
YOKOHAMA, 22 March, 2021/ REPROCELL has initiated a collaboration with Blacktrace Holdings Ltd in the sales of their Nadia series: a single-cell analytical system, in Japan.
17 March 2021
YOKOHAMA, March 16, 2021/ We are pleased to announce that our cell processing facility, REPROCELL Regenerative Medicine Center (located in Life Innovation Center in the Kanagawa region), was certified as manufacturing facility for cell culture products (registration number: FA3200006) on March 8th, 2021 by Kanto-Shinetsu Regional Bureau of Health and Welfare.
Hyderabad India – 11 March 2021: Bioserve Biotechnologies Pvt Ltd, 100% owned subsidiary of REPROCELL Inc, is pleased to announce the launch of Non-Invasive Prenatal Testing (NIPT) services in India.
1 March 2021
[Yokohama, Japan] REPROCELL will launch a new PCR testing service for COVID-19 from March 2021 in collaboration with DNAFORM Inc: a Japanese start-up company based on cutting-edge technologies developed by RIKEN, Japan’s largest comprehensive research institute.
25 February 2021
All patients have been registered at ten sites in Japan for the Phase II clinical trial of Stemchymal®, a human adipose-derived stem cell product exclusively licensed in Japan by Steminent Biotherapeutics Inc. (hereinafter referred to as Steminent), where the safety and efficacy of the regenerative therapeutic will be evaluated in patients with spinocerebellar ataxia (SCA).
17 December 2020
17 December 2020 [Japan, Yokohama]: REPROCELL has announced that they will launch a new service to generate individual specific induced pluripotent stem cell (iPSC) in January, “Personal iPS” service. REPROCELL will start taking orders from January 2021 in Japan. REPROCELL has also launched a new B2C website to promote the Personal iPS service, which is currently only available in Japan.
Rotterdam, The Netherlands, VIROCLINICS-DDL is pleased to announce the signing of a new collaboration agreement with REPROCELL. REPROCELL will provide sample processing services to VIROCLINICS-DDL to support several clinical research projects.
Yokohama, Japan: REPROCELL is delighted to announce the launch a new service for consumers, Personal iPS, in which induced pluripotent stem cells (iPSCs) are established for future regenerative medicine treatment.
28 February 2020
REPROCELL is pleased to announce that the first patient has been registered and the test article administered at Nagoya University in the Phase II clinical trial of the regenerative medicine product Stemchymal®.
Sign up to receive information from REPROCELL about our products, services, applications, promotions, and news (includes a weekly blog update email).